TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

NCT02186301 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

100

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor discontinued development of CO-1686 for NSCLC

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Rociletinib Mono-Therapy
DRUG: Erlotinib Mono-Therapy

Sponsor

Clovis Oncology, Inc.